Meiragtx Holdings PLC 10-Q quarterly reports

MeiraGTx Holdings plc announced a substantial increase in revenue for the six-month period ended June 30, 2026, driven by strategic collaborations and a robust cash position, while continuing to invest heavily in its gene therapy pipeline.

MeiraGTx Holdings plc filed its Q1 2026 Form 10-Q, detailing a net loss of $46.3 million and strategic advancements in its gene therapy pipeline, including the reacquisition of bota-vec.

MeiraGTx reports continued net losses in Q3 2025 but strengthens its financial position with significant upfront payments from new strategic collaborations with Eli Lilly and Hologen.

MeiraGTx reports increased Q2 losses but highlights a significant strategic collaboration with Hologen, securing substantial funding and advancing multiple gene therapy programs towards commercialization.

MeiraGTx Holdings plc announces its Q1 2025 financial results, emphasizing a strategic collaboration with Hologen, clinical advancements in AAV-GAD for Parkinson's disease, and progress in other gene therapy programs.

MeiraGTx Holdings reports a net loss of $39.3 million for the third quarter of 2024, with service revenue of $10.9 million and ongoing clinical development programs.

MeiraGTx Holdings reports a net loss of $69.1 million for the first six months of 2024, while highlighting progress in clinical trials and strategic collaborations.

MeiraGTx's Q1 2024 report details a net loss of $20.4 million, offset by a $50 million milestone payment and progress in clinical trials.